Investor Relations

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

View company overview

News releases

View all
May 18, 2026

RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: RBC CM Global Healthcare Conference Date and Time: Tuesday, May 19 at 9:30

Read more
May 11, 2026

Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results.

Read more
Apr 22, 2026

Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence  Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today

Read more